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Abstract
Background: Tuberculosis (TB) is the leading killer of people living with HIV (PLHIV). Many of these deaths occur in
developing countries. This study aimed at determining the incidence and predictors of tuberculosis among PLHIV.
Methods: A five year retrospective follow up study was conducted among adult PLHIV. The Cox proportional
hazards model was used to identify predictors.
Results: A total of 470 patients were followed and produced 1724.13 Person-Years (PY) of observation, and 136
new TB cases occurred during the follow up period. The overall incidence density of TB was 7.88 per 100 PY.
It was high (95.9/100PY) in the first year of enrolment. The cumulative proportion of TB- free survivals was 79%
and 67% at the end of the first and fifth years, respectively. Baseline WHO clinical stage III (AHR = 2.88, 95%
CI = 1.53-5.43), WHO clinical stage IV (AHR = 3.82, 95% CI = 1.86-7.85), CD4 count <50 cell/ul (AHR = 2.13, 95%
CI = 1.28-3.53) and ambulatory or bed ridden functional status (AHR = 1.64, 95%CI = 1.13-2.38) were predictors
of time to TB occurrence.
Conclusions: TB incidence rate among PLHIV, especially in the first year of enrollment was high. Advanced WHO
clinical stage, limited functional status, and low CD4 count (<50 cell cell/ul) were found to be the independent
predictors of TB occurrence. Early care seeking and initiation of HAART to improve the CD4 count and functional
status are important to reduce the risk of TB infection.
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Background
TB is a major public health problem and the most fre-
quently diagnosed opportunistic infection among PLHIV
worldwide [1,2]. It is still the leading killer of PLHIV
causing one in four deaths mostly in developing coun-
tries [3]. Worldwide, about 11.1 million adults most of
whom live in Sub-Saharan Africa are co-infected [4].
The main reason for the resurgence of TB in Africa is
not the deterioration of control programs; it is rather the
link between TB and HIV/AIDS in addition to the lack
of adequate economic and human resources. People with
a latent infection of mycobacterium tuberculosis (MTB),
which accounts for about one-third of the inhabitants of
Sub-Saharan Africa, are at a greater risk of developing
active TB if they are also immunologically weakened by
concurrent HIV infection [5]. In HIV infected individ-
uals, the presence of TB increases the occurrence of
other opportunistic infections and HIV replication that
lead to an increased viral load which in turn results in a
more rapid progression of HIV disease. One third of all
PLHIV worldwide are latently infected with MTB, mak-
ing them 21–34 times more likely to develop active TB
than people who are HIV negative [5-7]. Late TB diag-
nosis contributes to increased death rates among PLHIV
[4]. The management of a TB and HIV co-infected
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individual is challenging because of pill burden [8], in-
creased drug adverse effects [9], drug interaction [10]
and the immune reconstitution inflammatory syndrome
(IRIS) [11].
In Ethiopia, TB/HIV co-infected individuals have a
greater risk of common mental disorders, low quality of
life, and poor physical health than HIV infected individ-
uals without active TB [12,13]. In recent years, great ef-
forts have been made to integrate TB diagnosis and
treatment with HIV care in order to prevent, diagnose
and treat TB among PLHIV. This needs an adequate un-
derstanding of the situation through additional research
in the study area where TB incidence rate and associated
factors are not yet studied. This study, therefore,
aimed at determining the incidence and predictors of
TB among PLHIV who attended ART care at Gondar
University Referral Hospital.
Methods
Study design and setting
A five-year institution based retrospective follow up
study was conducted at the University of Gondar Refer-
ral Hospital, a teaching hospital in Gondar town, north-
west Ethiopia. The hospital serves more than five million
people of North Gondar and neighboring zones. The
HIV care service in this hospital was initiated in 2005
with three clinics: The Adult Anti-Retroviral Therapy
(ART) Clinic, Pediatric ART Clinic, and VCT Clinic.
Currently, more than 7,000 patients are in active follow-
up, of which over 3,888 have been initiated on highly ac-
tive antiretroviral treatment (HAART). The hospital uses
standardized monitoring and evaluation tools, and the
data collection and management processes are well con-
trolled and supported by electronic data back-up and
processing. Patient data, including socio-demographic
characteristics, like age, sex, residence, family size, level
of education, occupation, marital status, substance use,
and disclosure status are recorded on enrollment in the
HIV Program. The patient database also includes infor-
mation on WHO clinical stage, CD4 counts, Haemoglo-
bin level (Hgb), and HAART.
The treatment is given based on the national HAART
guidelines of the Ethiopian Federal Ministry of Health
which consists of daily cotrimoxazole prophylaxis for pa-
tients in clinical stage 2, 3 or 4 ( irrespective of CD4
count) or CD4 <350 irrespective of WHO clinical stage.
After ruling out active TB, isoniazid prophylaxis is con-
sidered in order to protect the PLHIV from developing
TB disease. HAART is initiated when the CD4 count <
200 cells/mm3 at any WHO clinical stage or WHO clin-
ical stage 4 (no matter what the CD4 count) or WHO
clinical stage 3 (if the CD4 count < 350 cells/mm3).
First-line HAART consists of two non-nucleoside reverse
transcriptase inhibitor stavudine (d4T) or zidovudine
(AZT) in combination with lamivudine (3TC) plus a
non-nucleoside reverse transcriptase inhibitor in stand-
ard doses (nevirapine (NVP) or efavirenz (EFV)). The
choice of HAART combination is up to decision of the
physician and the availability of the drug at the time of
initiation.
Definitions of tuberculosis
TB is diagnosed using microscopic examinations of spu-
tum smears, chest radiology, and fine-needle aspiration
of lymphadenopathy and cytology with very high clinical
grounds. No mycobacterial culture facilities are available
in the hospital. When patients are diagnosed with active
TB, the treatment is given according to the National TB
Program recommendations with a standard 8 month
regimen with an 8 week, 4 drug (isoniazid, rifampicin,
ethambutol and pyrazinamide) intensive phase and a
subsequent 6 month, 2 drug (isoniazid, ethambutol) con-
tinuation phase. Incident TB, which is defined in this
study, as an event, during follow-up was ascertained
retrospectively when the patient is diagnosed for TB and
starts anti TB treatment. PLHIV who were not diag-
nosed for TB until the end of the follow up period were
considered as censored.
Inclusion and exclusion criteria
All PLHIV aged 15 years and above and were newly
enrolled into the adult chronic HIV care clinic at the
University of Gondar Referral Hospital from September
11, 2006 to August 31, 2007, were included in the study
and followed for five years, until February 29, 2012. This
period was selected in order to have the nearest five year
follow up study period. In this period the facility started
full implementation of standardized formats, documen-
tation, and a recording system in a regular manner. A
total of 529 PLHIV were registered during the period
out of whom 59 patients were excluded due to missing
charts or incomplete baseline and follow-up data.
Data collection
All available information on patient records was
checked and an appropriate data extraction format was
prepared. Then, data were extracted from patients’
charts by four nurses who had ART training and ex-
perience in HIV care.
Data analysis
Data were cleaned and entered into a computer using
EPI info version 3.5.3 statistical software and exported to
the Statistical Package for Social Science (SPSS) version
20 for analysis. Summary statistics and Incidence Dens-
ity Rate (IDR) were calculated. To calculate TB inci-
dence among PLHIV, the total duration of follow-up for
the whole cohort in PY was used. The duration of
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follow-up for PLHIV who did not develop TB was calcu-
lated from the time of enrolment in the HIV Care Pro-
gram until the last visit. For these people, the total
duration of follow-up was considered TB-free. For
PLWH who developed TB, the TB-free follow-up was
calculated from the time of enrolment in the HIV Care
Program until the development of TB. Subsequently, the
number of TB cases within the cohort was divided by
the TB-free follow-up duration and reported per 100 PY.
As this study has considered time-to-event data, the
survival analysis technique was carried out, Cox propor-
tional hazards model was fitted, and a life table was used
to estimate cumulative probabilities. The Kaplan-Meier
curve (an intuitive graphical presentation which de-
scribes survivorship of the study population) was used to
estimate the median duration of TB occurrence. The
Log rank test was used to compare survival curves be-
tween different categories of explanatory variables. Bi-
variate and multivariate Cox proportional hazard models
were used to identify the predictors of TB occurrence.
Variables with p value < 0.2 in the bivariate analysis were
entered into the multivariate proportional hazard model.
Hazard Ratios (HR) with 95% confidence intervals were
computed and statistical significance was accepted at the
5% level (p < 0.05). The necessary assumptions for Cox
proportional hazard model were checked using the
Schoenfield residuals test.
Ethical issues
Ethical clearance was obtained from the institutional re-
view board of the Institute of Public Health, the University
of Gondar. Letter of permission was obtained from the
Chief Executive Officer of the hospital. The department
head of the HIV care clinics gave the consent for extracting
data from records. Patient names and identification
numbers were not extracted so as to ensure confidentiality
of patient information.
Results
Four hundred seventy records of PLHIV were analyzed.
Their mean age was 33.22 (± 7.8 SD) years and almost
half, 222 (47.2%), of them were in the age group of 25–
34 years. Over half (61.9%) of the PLHIV were females
and the majority (87.7%), of them were urban dwellers.
A total of 364 (77.4%) patients disclosed their HIV sta-
tus, to their brothers/sisters (29.8%), to parents (25.3%).
Three hundred eight patients (67.7%) were addicted to
alcohol (26.8%), to tobacco (9.4) or to drugs 17 (3.6%)
(Table 1). The eligibility criterion for initiation of
HAART was mainly the WHO Clinical Stage in 282
(60.0%). More than half (62.6%) of them were at WHO
clinical stage 3 during enrolment. Three hundred forty
two (72.8%) of the participants were on working func-
tional status at baseline. The median CD4 count during
Table 1 Baseline socio demographic and clinical
characteristics of PLHIV on chronic HIV care at University of
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enrollment and end of follow up was 135 [IQR: 70–207]
and 335[IQR: 225–478] cells per mm3, respectively. The
predominant regimens initially prescribed were a
combination of zidovudine, Lamivudine and Nevira-
pine (38.3%), followed by Stavudine, Lamivudine and,
Nevirapine (26.8%). One hundred eighty four (39%)
patients had changed their initial regimen during the
follow up period mainly to a combination of zidovu-
dine, Lamivudine and Nevirapine (1c) 45(9.6%). Nine
(1.9%) patients were switched to second line HAART.
For 34(7.2%) and 29(6.1%) patients, regimens were
changed due to drug side effect and TB, respectively
while the reasons for changing the initial regimen
were not recorded for 99 (21.1%) patients. Half of the
HAART regimens were changed within the first year
of follow up (Table 2).
Tuberculosis incidence density
Four hundred seventy study participants who were
followed for different periods in five years produced
1724.13 PY of observation. Within the follow up period,
136 new TB cases were observed. The overall TB inci-
dence density was 7.89 per 100 PY. Among the new TB
cases, 64 were males and 72 females. Of these, 81(17.2%)
were pulmonary TB and 18(3.8%) were Extra-pulmonary
and/or Disseminated TB. Ninety four (69.11%) of the TB
cases occurred within the first year of follow up. The
highest incidence of TB was observed in the first year of
enrolment (95.9/100 PY) and then decreased in the sub-
sequent years of follow up (34.0 and 1.6 per 100 PY in
three and five years, respectively). The cumulative prob-
ability of TB-free survival at the end of 6 months was
0.80; where surviving at the end of one year was 0.79; at
the end of two years 0.78; at the end of three years 0.76;
at the end of four years 0.72 and at the end of five years
0.67. The median survival time from enrolment to
chronic HIV care to TB occurrence was 60 month
(Figure 1).
Predictors of time to TB occurrence
In the multivariate Cox-regression analysis, baseline
CD4 cell count, WHO clinical stage and functional sta-
tus remained significant predictors of TB- free survival
time. Accordingly, PLHIV who were ambulatory or bed
ridden at enrollment, were 1.64 times at higher risk of
developing TB at any time compared to those who were
working (AHR = 1.64, 95%CI = 1.13-2.38). The PLHIV
who were at WHO clinical stage III had about three
times higher risk of acquiring TB at any time compared
to those with WHO clinical stage I or II (AHR = 3.26,
95%CI = 1.74-6.10). Similarly, PLHIV with WHO clinical
stage IV were about four times at higher risk of TB ac-
quisition at any time than those with WHO clinical stage
I or II (AHR = 3.82, 95%CI 1.86-7.85) (Figure 2). A pa-
tient with a CD4 count of less than 50 cell/ul is 2.47
times more likely to have TB at any time than a patient
Table 1 Baseline socio demographic and clinical
characteristics of PLHIV on chronic HIV care at University of
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with a CD4 count greater than 200 cell/ul (AHR =
2.47,95% CI 1.49-4.09) (Figure 3).
Discussion
HIV positive people are 20 times at higher risk of devel-
oping TB as compared to HIV negative people in coun-
tries with a generalized HIV epidemic [14]. TB is also
the most common cause of death among PLHIV [3]. In
this study, the overall incidence of TB was 7.89 per 100
PY. It was similar with that of studies done in Ethiopia
and many other Sub Sahara African countries with
reported incidences ranging from 5.4 to 11 per 100 PY
[15-18]. But, this finding is higher than that of studies
done in Brazil and Taiwan which were 3.8% and 4.01/
100 PY, respectively. This could be explained by the fact
that unlike these two countries, Ethiopia is one of the
high TB burden countries [2]. Studies also revealed that
in very high burden countries the incidence of TB
among individuals on HAART was high [19].
The highest incidence of TB was observed in the first
year of enrolment. This observation was in line with the
Table 2 Tuberculosis incidence density rate stratified by
socio-demographic and clinical characteristics of PLHIV
on chronic HIV care at University of Gondar Referral
Hospital, September 2006 to February, 2012
Characteristics Total PY TB TB IDR
Age (years)
15-24 47 180.20 13 7.21
25-34 222 810.68 64 7.89
35-44 154 569.84 45 7.89
≥ 45 47 163.41 14 8.56
Sex
Male 179 594.82 64 10.76
Female 291 1129.31 72 6.37
Marital status
Never married/single 78 280.87 24 8.54
Married 178 652.79 51 7.81
Separated/divorced 144 526.85 40 7.59
Widowed/er 70 263.61 21 7.96
Religion
Orthodox 431 1585.37 126 7.94
Muslim 34 119.71 9 7.52
Protestant 5 19.05 1 5.23
Educational status
No education 127 501.87 31 6.17
Primary 135 464.72 46 9.89
Secondary 138 510.56 38 7.44
Tertiary 70 246.98 21 8.50
Occupation
Employed 94 351.48 24 6.83
Unemployed 376 1372.65 112 8.16
Residence
Urban 412 1515.84 122 8.05
Rural 58 208.29 14 6.72
Disclosure Status
Disclosed 364 1303.46 110 8.44
Not Disclosed 106 420.67 26 6.18
Addiction
Addicted 318 1186.85 89 6.83
Not Addicted 152 537.28 47 8.74
Total 470 1724.13 136 7.89
Initial regimen
1a 126 487.06 32 6.57
1b 56 145.15 28 19.29
1c 180 715.15 38 5.31
1d 97 332.51 34 10.22
Others* 8 30.28 4 13.21
Table 2 Tuberculosis incidence density rate stratified by
socio-demographic and clinical characteristics of PLHIV
on chronic HIV care at University of Gondar Referral
Hospital, September 2006 to February, 2012 (Continued)
Past TB treatment history
Yes 153 540.89 54 9.98
No 226 859.10 58 6.75
Functional status
Working 342 1342.08 79 5.88
Ambulatory 110 331.91 48 14.46
Bed ridden 18 50.2 9 17.93
WHO clinical stage
I 25 105.38 3 2.84
II 77 340.55 8 2.35
III 294 1073.84 92 8.56
IV 74 204.37 33 16.14
CD4 count
<50 77 226.15 36 15.91
50-100 100 364.10 25 6.86
101-200 169 640.07 48 7.49
>200 124 493.80 27 5.46
Hgb
<10 48 161.30 16 9.92
≥ 10 422 1562.83 120 7.68
Year of follow up
≤ 1 98 98 94 95.92
1-3 20 44.08 15 34.02
≥ 3 352 1664.79 27 1.62
Addis Alene et al. BMC Infectious Diseases 2013, 13:292 Page 5 of 9
http://www.biomedcentral.com/1471-2334/13/292
Figure 1 Kaplan-Meier curve of TB survival proportion for PLHIV on Chronic HIV care at the University of Gondar Referral Hospital,
September 2006 to February, 2012.
Figure 2 Kaplan-Meier survival curve of TB-free proportion based on WHO Clinical Stage among PLHIV on chronic HIV care at
University of Gondar Referral Hospital, September 2006 to February, 2012.
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evidence of declining TB incidence after enrolment and
HAART initiation reported in cohorts of HIV-infected
persons in Sub-Saharan Africa [20] and Ethiopia [17].
The Peak TB incidence shortly after enrollment may
have several explanations. Firstly, it may represent the
progression of a subclinical disease that remained un-
detected during enrollment and a rapid progression of
either a newly reactivated disease or an exogenous
Figure 3 Kaplan-Meier curve of Tuberculosis -free survival proportion based on baseline CD4 cell count at enrolment at the University
of Gondar Referral Hospital from September 2006 to February, 2012.
Table 3 Cox regression analysis of predictors of tuberculosis among PLHIV cohorts on chronic HIV car at University of
Gondar referral Hospital from September 2006 to February, 2012
Variable Survival status Total CHR, (95%CI) AHR, (95% CI)
Event (TB) Censored
Sex
Male 64 115 179 1.58 (1.13-2.22) 1.4 (0.99-1.98)
Female 72 219 291 1.00 1.00
Tobacco use
Yes 18 26 44 1.64(1.00-2.70) 1.46(0.85-2.49)
No 118 306 424 1.00 1.00
Functional status
Working 79 263 342 1.00
Ambulatory/Bed ridden 57 71 128 2.27(1.61 3.19) 1.64(1.13-2.38)
WHO clinical stage
I/II 91 11 102 1.00
III 202 92 294 3.26(1.74 ,6.10) 2.88(1.53-5.43)
IV 41 33 74 5.55(2.80, 0.99) 3.82(1.86-7.85)
CD4 cell count
<50 41 36 77 2.61(1.58-4.30) 2.13(1.28-3.53)
50-200 196 73 269 1.28(0.82,1.99) 1.27(0.81-1.98)
>200 97 27 124 1.00 1.00
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infection. Secondly, immune reconstitution inflamma-
tory syndrome (IRIS) may have been responsible for
some of these cases. TB is the most frequently reported
IRIS associated infection [21]. Though the available data
did not permit making this distinction, it was known
that IRIS occurred in the early initiation of HAART [22].
The result of this study showed that large numbers of
patients started HAART within the first year of follow
up which led to the development of IRIS. The finding
also showed a significant decrease in TB incidence in
the subsequent years of follow up. These indirectly indi-
cated that the reduction in TB incidence following the
introduction of HAART can be particularly linked with
HAART induced prevention. A study done at Arba
Minch Hospital, Ethiopia, showed that TB incidences
were 3.7 and 11.1 per 100 PY in the ART and Pre ART
groups, respectively [23]. Other findings [17,24,25],
revealed that HAART reduces the risk of TB in line with
our study. Thirdly, the other possible reason for increased
TB- free survival within the duration of enrolment could
be the result of progressive increase in CD4 cell count
which builds the immune system and may decrease the
viral load over time. Although TB risk has decreased with
time following enrolment, it was still significantly higher
than that of the general population of Ethiopia, even after
5 years of follow up. In this study, the incidence of TB at
the end of the follow up period was 1.6 per 100 PY, which
was four fold higher than the overall TB rate in Ethiopia
which was approximately 0.38/PY [14]. This might be due
to the synergy between TB and HIV co-infection.
In the analysis, predictors significantly associated with
TB-free survival time were bedriddenness or ambulatory
functional status, advanced WHO clinical stage, and low
CD4 count at baseline (Table 3). All these predictors
were also identified in previous studies [16,18,26]. WHO
clinical stage III had 3 times higher risk of TB incidence
at any time than WHO clinical stage I or II. Further-
more, the risk is five times higher in WHO clinical stage
IV which is in line with a study done in Nigeria [16].
Even though TB can occur at any WHO clinical stage it
is more common in advanced clinical stages [6]. This re-
search has also found that patients with ambulatory or
bed ridden baseline functional status were 1.45 times at
higher risk of developing TB than those with working
functional status. This could be due to the fact that pa-
tients become bed ridden or ambulatory as a result of
many infectious diseases as their CD4 cell count de-
crease. The baseline CD4 count of <50 cells/ μl was a
very strong and independent risk factor of TB in patients
enrolled to chronic HIV care (AHR = 2.13, 95% CI =
1.28-3.53).A lower baseline CD4 count before initiation
of HAART has consistently been indicated as an inde-
pendent risk factor for the occurrence of TB during the
course of HIV treatment and care in different settings
[16,18,26]. A study in West Africa indicated that a base-
line CD4 count had no association with the occurrence
of TB during HAART [27]. That was because the study
had limitations in design relating to the size of the study
population, the number of TB cases, diagnostic criteria
for tuberculosis, and restricted cohort composition.
The main limitation of our study was the retrospective
nature of the cohort. The study participants whose
charts were lost were not included in the study, perhaps
undermining the result if the charts excluded were re-
lated to TB.
Conclusion
Incidence of TB was high among people living with
HIV, especially in the first year of enrollment in
chronic HIV care. WHO clinical stage III and IV, am-
bulatory or bed ridden functional status, and low
CD4 count (<50 cell/ul) were found to be independ-
ent predictors of TB-free survival time. Therefore, it
is important to give special attention to PLHIV in
diagnosing, preventing and treating TB early. TB/HIV
collaborative long term surveillance programs should
be strengthened at chronic HIV care clinics with early
initiation of HAART as recommended in the national
guideline.
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